(NCT number: pending)
As many as 40–50% of children, adolescents, and young adults with chronic tic disorders continue to experience significant and impairing symptoms despite receiving evidence-based treatments such as behavioral therapy (CBIT) and medication.
This goal of this pilot study is to determine whether TMS administered to one of two assigned stimulation sites is acceptable and shows evidence of benefit in adolescents and young adults with tic disorders. The study is led by Drs. James McCracken and A. Moses Lee.
TMS is a noninvasive brain stimulation treatment that uses magnetic pulses applied to the scalp to stimulate targeted brain regions. TMS is FDA-approved for treatment-resistant OCD and depression in adults and has been shown to be safe in children and adolescents, but TMS is not currently FDA approved for treatment of tic disorders.
If eligible, participants (ages 15–35) will receive a 2-week intensive course of TMS treatment under close monitoring, as well as MRI scans of the brain before and after treatment. If you are interested in participating, please fill out our interest form below.